Diaverum acquires new clinic in Spain

NewsGuard 100/100 Score

Continuing on a path of international growth, Diaverum, the largest independent provider of renal health care service in Europe, has surpassed the 200 clinic mark with the acquisition of a new center near Barcelona, Spain.

“We are bringing innovation and change to the marketplace as we focus on providing the world’s best renal care”

“We are delighted with the continued expansion of Diaverum. It means that we further strengthen our market leadership in the Province of Barcelona and also in Catalonia overall,” says Dag Andersson, Chief Executive Officer of Diaverum. “We are bringing innovation and change to the marketplace as we focus on providing the world’s best renal care”.

The new clinic, which provides treatment for 170 patients suffering from end stage renal disease, represents the 25th Diaverum clinic in Spain. ”We are now providing the highest quality renal care services to more than 16,000 people with chronic renal disease in our Diaverum clinics in 14 countries.

We are very proud to be able to offer this quality of care, which is provided by our dedicated and passionate personnel, resulting in a high level of patient satisfaction”, remarks Andersson.

During 2009, Diaverum added 20 clinics to its worldwide clinic network, and during 2010 the company has the intention to continue its growth in existing and new markets, and add new service offerings centered around the needs of renal patients.

Source:

http://www.cisionwire.com

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Diabetes management program cuts dementia risk in type 2 patients